FGEN

0.2996

4.50% 0.0129

Vorhandelsmarkt: .31 0.0104 +3.47%

Fibrogen Inc (FGEN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt FGEN? Forum Prognose

Schlusskurs vom Vortag:

$0.2867

Offen:

$0.3

24-Stunden-Volumen:

376.98K

Relative Volume:

0.12

Marktkapitalisierung:

$29.89M

Einnahmen:

$147.75M

Nettoeinkommen (Verlust:

$-284.23M

KGV:

-0.1023

EPS:

-2.93

Netto-Cashflow:

$-317.54M

1W Leistung:

+1.15%

1M Leistung:

-4.89%

6M Leistung:

-14.47%

1J Leistung:

-73.72%

1-Tages-Spanne:

$0.2874

$0.3024

1-Wochen-Bereich:

$0.2703

$0.3092

52-Wochen-Spanne:

$0.18

$1.74

Fibrogen Inc Stock (FGEN) Company Profile

Firmenname

Fibrogen Inc

Sektor

Healthcare (1153)

Branche

Biotechnology (665)

Telefon

415-978-1200

Adresse

350 BAY STREET, SAN FRANCISCO, CA

Mitarbeiter

225

Twitter

@FibroGenInc

Nächster Verdiensttermin

2025-03-17

Neueste SEC-Einreichungen

FGEN's Discussions on Twitter

Vergleichen Sie FGEN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FGEN Fibrogen Inc	0.2996	29.89M	147.75M	-284.23M	-317.54M	-2.93
VRTX Vertex Pharmaceuticals Inc	490.47	128.67B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	585.49	60.99B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	599.87	36.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	236.75	29.89B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	252.77	25.74B	3.81B	-644.79M	-669.77M	-6.24

Fibrogen Inc Stock (FGEN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-08-08	Herabstufung	BofA Securities	Neutral → Underperform
2023-06-26	Herabstufung	BofA Securities	Buy → Neutral
2023-06-26	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-06-26	Herabstufung	Stifel	Buy → Hold
2023-06-26	Herabstufung	William Blair	Outperform → Mkt Perform
2023-06-02	Hochstufung	Stifel	Hold → Buy
2023-01-31	Hochstufung	William Blair	Mkt Perform → Outperform
2023-01-26	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-01-05	Hochstufung	BofA Securities	Neutral → Buy
2021-09-22	Herabstufung	Goldman	Neutral → Sell
2021-08-20	Hochstufung	Raymond James	Underperform → Mkt Perform
2021-07-16	Herabstufung	BofA Securities	Buy → Neutral
2021-07-16	Herabstufung	Stifel	Buy → Hold
2021-04-07	Herabstufung	H.C. Wainwright	Buy → Neutral
2021-04-07	Herabstufung	Mizuho	Buy → Neutral
2021-03-31	Hochstufung	BofA Securities	Neutral → Buy
2021-03-02	Herabstufung	Jefferies	Buy → Hold
2021-02-01	Eingeleitet	H.C. Wainwright	Buy
2020-10-26	Eingeleitet	Raymond James	Underperform
2020-07-10	Fortgesetzt	Stifel	Buy
2020-05-01	Eingeleitet	Cowen	Market Perform
2020-04-27	Eingeleitet	BofA/Merrill	Neutral
2019-05-29	Fortgesetzt	Goldman	Neutral
2019-05-10	Herabstufung	William Blair	Outperform → Mkt Perform
2019-04-12	Eingeleitet	Piper Jaffray	Neutral
2019-02-11	Fortgesetzt	Stifel	Buy
2018-12-19	Hochstufung	Citigroup	Neutral → Buy
2017-08-08	Bestätigt	Leerink Partners	Outperform
2017-08-08	Bestätigt	Stifel	Buy
2017-07-21	Herabstufung	Goldman	Buy → Neutral
2017-07-11	Eingeleitet	Jefferies	Buy
2016-02-11	Hochstufung	Credit Suisse	Neutral → Outperform
2016-01-21	Eingeleitet	Credit Suisse	Neutral
2015-12-04	Eingeleitet	Citigroup	Buy
2015-09-23	Eingeleitet	Lake Street	Hold
2015-07-29	Eingeleitet	Citigroup	Buy
2015-07-20	Hochstufung	Goldman	Neutral → Buy
2014-12-09	Eingeleitet	Stifel	Buy

Alle ansehen

Fibrogen Inc Aktie (FGEN) Neueste Nachrichten

Apr 11, 2025

FGEN Stock Price and Chart — NASDAQ:FGEN - TradingView

Apr 11, 2025

Apr 08, 2025

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26% - simplywall.st

Apr 08, 2025

Apr 02, 2025

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire

Apr 02, 2025

Apr 01, 2025

William Blair Keeps Their Hold Rating on FibroGen (FGEN) - The Globe and Mail

Apr 01, 2025

Mar 30, 2025

FibroGen extends merger option deadline with Fortis - Investing.com Australia

Mar 30, 2025

Mar 28, 2025

FibroGen extends merger option deadline with Fortis By Investing.com - Investing.com South Africa

Mar 28, 2025

Morgan Stanley’s Adam Jonas Is Pounding the Table on This 1 ‘Unique’ Stock - The Globe and Mail

Mar 28, 2025

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology - The Manila Times

Mar 28, 2025

FibroGen reports promising FG-3246 study results for prostate cancer - Investing.com

Mar 28, 2025

Mar 27, 2025

1 Top Cryptocurrency to Buy Before It Soars 14,623%, According to Michael Saylor - The Globe and Mail

Mar 27, 2025

Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock By Investing.com - Investing.com Australia

Mar 25, 2025

Fibrogen CEO Wettig Thane buys $50,663 in common stock - Investing.com India

Mar 25, 2025

Mar 24, 2025

Fibrogen director James Schoeneck buys $105,040 in stock By Investing.com - Investing.com Canada

Mar 24, 2025

Mar 20, 2025

In the Red? AstraZeneca Acquires FibroGen, Inc.’s China Subsidiary - Law Street Media

Mar 20, 2025

Mar 19, 2025

FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 19, 2025

FibroGen Full Year 2024 Earnings: Beats Expectations - Yahoo

Mar 19, 2025

Mar 18, 2025